Core Insights - Scienture Holdings, Inc. reported significant revenue growth of 216% in 2025, reaching $431.6 million, driven by the successful launch of its product Arbli in the U.S. losartan market [4][5][7] - The company achieved a gross margin expansion to 76.8%, up from 4.4% in 2024, reflecting a shift to higher-margin branded pharmaceutical sales [5][7] - Scienture is positioned for continued growth with plans for the commercial launch of REZENOPY in 2026, targeting the opioid overdose treatment market [4][6] Financial Highlights - Net revenue increased by 216% to $431,609 in 2025 from $136,643 in 2024 [5][7] - Gross profit rose to $331,482 in 2025 compared to $6,005 in 2024, with gross margin increasing by 7,240 basis points [5][7] - Operating expenses totaled $42.9 million, primarily due to a one-time, non-cash impairment charge of $26.3 million [8][31] Operational Highlights - The launch of Arbli captured strong early commercial traction in a $241 million U.S. losartan market, with 72 million prescriptions annually [4][6] - Scienture secured multiple PBM-led GPO rebate agreements, enhancing commercial coverage for Arbli [5] - The company established a strategic collaboration with BlinkRx to improve patient access and adherence for Arbli [5] Product Information - Arbli is the first FDA-approved ready-to-use oral liquid formulation of losartan, designed for treating hypertension [10][11] - REZENOPY is a naloxone nasal spray indicated for emergency treatment of opioid overdose, with a significant market opportunity in the U.S. [6][16] Market Position - Scienture's GPO agreements for REZENOPY expand access to over 5,000 healthcare institutions, covering approximately 60% of the U.S. institutional market [6] - The U.S. naloxone market is valued at approximately $141 million, with REZENOPY positioned to capture market share [6]
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update